Parker Singleton
@parkersingleton.bsky.social
Senior Scientist at Penn Lifespan Informatics and Neuroimaging Center (PennLINC) studying psychedelics and the brain.
sypres.io
sypres.io
In partnership with metapsy.org we built an interactive dashboard for exploring the data. Users can:
• Filter studies by characteristics
• Test different analysis parameters
• Test moderators
• Download figures and reports
Dashboard: metapsy.org/sypres/psilo...
• Filter studies by characteristics
• Test different analysis parameters
• Test moderators
• Download figures and reports
Dashboard: metapsy.org/sypres/psilo...
August 18, 2025 at 1:17 PM
In partnership with metapsy.org we built an interactive dashboard for exploring the data. Users can:
• Filter studies by characteristics
• Test different analysis parameters
• Test moderators
• Download figures and reports
Dashboard: metapsy.org/sypres/psilo...
• Filter studies by characteristics
• Test different analysis parameters
• Test moderators
• Download figures and reports
Dashboard: metapsy.org/sypres/psilo...
Our database includes 200+ effect sizes, encompassing all depression outcomes and timepoints reported by arm in each of the 12 RCTs included. This database can be downloaded from our website (sypres.io) or imported directly into R environments using the metapsyData package from metapsy.org
August 18, 2025 at 1:17 PM
Our database includes 200+ effect sizes, encompassing all depression outcomes and timepoints reported by arm in each of the 12 RCTs included. This database can be downloaded from our website (sypres.io) or imported directly into R environments using the metapsyData package from metapsy.org
Here, psilocybin showed a greater reduction in depression scores compared to control conditions, with a pooled Hedges’ g = -0.91 (k = 9; p = 0.0013, I2 = 58.1%, n = 501). But important caveats—small studies, blinding challenges, risk of bias, and design heterogeneity, which we discuss in the paper.
August 18, 2025 at 1:17 PM
Here, psilocybin showed a greater reduction in depression scores compared to control conditions, with a pooled Hedges’ g = -0.91 (k = 9; p = 0.0013, I2 = 58.1%, n = 501). But important caveats—small studies, blinding challenges, risk of bias, and design heterogeneity, which we discuss in the paper.
sypres.io is our new initiative featuring:
📊 Regularly updated meta-analyses
🔍 User-guided sensitivity and moderation analysis
🕵️ Transparent study quality & risk-of-bias assessments
⚙️ Open code & data
📊 Regularly updated meta-analyses
🔍 User-guided sensitivity and moderation analysis
🕵️ Transparent study quality & risk-of-bias assessments
⚙️ Open code & data
August 18, 2025 at 1:17 PM
sypres.io is our new initiative featuring:
📊 Regularly updated meta-analyses
🔍 User-guided sensitivity and moderation analysis
🕵️ Transparent study quality & risk-of-bias assessments
⚙️ Open code & data
📊 Regularly updated meta-analyses
🔍 User-guided sensitivity and moderation analysis
🕵️ Transparent study quality & risk-of-bias assessments
⚙️ Open code & data
Psychedelic science has experienced the benefits and drawbacks of hype. However, new results are rarely contextualized in the historical body of evidence in an accessible manner. We need more robust, living, evidence synthesis that is visible and accessible to all stakeholders.
August 18, 2025 at 1:17 PM
Psychedelic science has experienced the benefits and drawbacks of hype. However, new results are rarely contextualized in the historical body of evidence in an accessible manner. We need more robust, living, evidence synthesis that is visible and accessible to all stakeholders.
🍄 Our new living systematic review and meta-analysis on psilocybin for depression is out. Here's what we found and the open science infrastructure we built to support it 🧪🧵
www.medrxiv.org/content/10.1...
www.medrxiv.org/content/10.1...
August 18, 2025 at 1:17 PM
🍄 Our new living systematic review and meta-analysis on psilocybin for depression is out. Here's what we found and the open science infrastructure we built to support it 🧪🧵
www.medrxiv.org/content/10.1...
www.medrxiv.org/content/10.1...
yea, that random structure with a hypervalent nitrogen is definitely 5-meo-dmt
July 3, 2025 at 1:04 PM
yea, that random structure with a hypervalent nitrogen is definitely 5-meo-dmt
Lastly but not leastly, we used PK/PD modeling to recapitulate DMT's impacts on control energy - demonstrating that control models can predict (some) pharmacological effects on brain dynamics.
April 21, 2025 at 2:56 PM
Lastly but not leastly, we used PK/PD modeling to recapitulate DMT's impacts on control energy - demonstrating that control models can predict (some) pharmacological effects on brain dynamics.
We used dominance analysis to compare 2a's relative importance in explaining these regional metrics compared with other serotonin receptors. See the paper/SI for interesting negative controls using the placebo condition for the last two figures.
April 21, 2025 at 2:56 PM
We used dominance analysis to compare 2a's relative importance in explaining these regional metrics compared with other serotonin receptors. See the paper/SI for interesting negative controls using the placebo condition for the last two figures.
Three regional metrics correlated spatially with serotonin 2a density (from PET): a) the amount of control energy reduction by DMT, b) each region's temporal coupling between control energy and LZ, and c) each region's temporal coupling between control energy and drug intensity.
April 21, 2025 at 2:56 PM
Three regional metrics correlated spatially with serotonin 2a density (from PET): a) the amount of control energy reduction by DMT, b) each region's temporal coupling between control energy and LZ, and c) each region's temporal coupling between control energy and drug intensity.
Over time, control energy reductions by DMT (an fMRI measure) correlated with increases in Lempel-Ziv complexity (from EEG) and subjective drug intensity ratings.
April 21, 2025 at 2:56 PM
Over time, control energy reductions by DMT (an fMRI measure) correlated with increases in Lempel-Ziv complexity (from EEG) and subjective drug intensity ratings.
On a network level, these reductions were most prominent in the DMN, FPN, and VIS networks. Notably, in these three networks the effect was strongest during DMT's peak effects (first half) for the DMN and FPN, but the reverse was true for VIS. See paper for discussion on arousal.
April 21, 2025 at 2:56 PM
On a network level, these reductions were most prominent in the DMN, FPN, and VIS networks. Notably, in these three networks the effect was strongest during DMT's peak effects (first half) for the DMN and FPN, but the reverse was true for VIS. See paper for discussion on arousal.
Control energy (whole-brain) was reduced under DMT compared with placebo for ~2/3rds of post-injection time-points.
April 21, 2025 at 2:56 PM
Control energy (whole-brain) was reduced under DMT compared with placebo for ~2/3rds of post-injection time-points.
We deployed a time-resolved network control analysis of the brain's trajectory through its activational landscape to map control energy in the brain as it changes throughout the scanning sessions.
April 21, 2025 at 2:56 PM
We deployed a time-resolved network control analysis of the brain's trajectory through its activational landscape to map control energy in the brain as it changes throughout the scanning sessions.
The serotonergic psychedelic DMT induces a profoundly immersive altered state of consciousness lasting under 20 minutes, allowing the entire experience to be captured during a single scanning session. Here, we analyzed data from N=14 individuals under-going simultaneous EEG-fMRI.
April 21, 2025 at 2:56 PM
The serotonergic psychedelic DMT induces a profoundly immersive altered state of consciousness lasting under 20 minutes, allowing the entire experience to be captured during a single scanning session. Here, we analyzed data from N=14 individuals under-going simultaneous EEG-fMRI.
SYPRES (Synthesis of Psychedelic Research Studies) will be an open-access, online, interactive dashboard featuring:
📊 Regularly updated meta-analyses
🔍 User-guided sensitivity and moderation analysis
🕵️ Transparent study quality & risk-of-bias assessments
⚙️ Open code & data
📊 Regularly updated meta-analyses
🔍 User-guided sensitivity and moderation analysis
🕵️ Transparent study quality & risk-of-bias assessments
⚙️ Open code & data
January 10, 2025 at 4:12 PM
SYPRES (Synthesis of Psychedelic Research Studies) will be an open-access, online, interactive dashboard featuring:
📊 Regularly updated meta-analyses
🔍 User-guided sensitivity and moderation analysis
🕵️ Transparent study quality & risk-of-bias assessments
⚙️ Open code & data
📊 Regularly updated meta-analyses
🔍 User-guided sensitivity and moderation analysis
🕵️ Transparent study quality & risk-of-bias assessments
⚙️ Open code & data
In a media environment where individual studies get featured prominently in the NY Times, lay observers might think psychedelics are proven safe and effective 100 times over (i.e. hype). New results are rarely contextualized in the historical body of evidence in an accessible manner.
January 10, 2025 at 4:12 PM
In a media environment where individual studies get featured prominently in the NY Times, lay observers might think psychedelics are proven safe and effective 100 times over (i.e. hype). New results are rarely contextualized in the historical body of evidence in an accessible manner.
someone seriously needs to change this law
November 26, 2024 at 6:59 PM
someone seriously needs to change this law
Been wanting to do mushroom logs for years. Hurricane Helene provided the right wood at the right time so finally got it going. Hopefully we'll have shiitake abundance in several months. #fungifriends
November 18, 2024 at 2:20 AM
Been wanting to do mushroom logs for years. Hurricane Helene provided the right wood at the right time so finally got it going. Hopefully we'll have shiitake abundance in several months. #fungifriends
Howdy yall, I help organize webinar called "Machine Learning in Medicine" that all are free to join.
In 10 minutes we have Lena Maier-Hein presenting on the importance of scientific rigor in medical imaging AI.
Hop in and see what its about!
weillcornell.zoom.us/j/92581271707
Passcode: 437063
In 10 minutes we have Lena Maier-Hein presenting on the importance of scientific rigor in medical imaging AI.
Hop in and see what its about!
weillcornell.zoom.us/j/92581271707
Passcode: 437063
November 10, 2023 at 2:53 PM
Howdy yall, I help organize webinar called "Machine Learning in Medicine" that all are free to join.
In 10 minutes we have Lena Maier-Hein presenting on the importance of scientific rigor in medical imaging AI.
Hop in and see what its about!
weillcornell.zoom.us/j/92581271707
Passcode: 437063
In 10 minutes we have Lena Maier-Hein presenting on the importance of scientific rigor in medical imaging AI.
Hop in and see what its about!
weillcornell.zoom.us/j/92581271707
Passcode: 437063
Me simply not getting desk rejected by frontiers:
November 1, 2023 at 11:18 PM
Me simply not getting desk rejected by frontiers:
Howdy #machinelearning in #medicine folks. Will be hosting this seminar in a half hour - all are free to join.
Helen Zhou:
"Towards Characterizing and Adapting to Shifts in Medical Data over Time" weillcornell.zoom.us/j/9258127170... 437063
Helen Zhou:
"Towards Characterizing and Adapting to Shifts in Medical Data over Time" weillcornell.zoom.us/j/9258127170... 437063
October 13, 2023 at 1:27 PM
Howdy #machinelearning in #medicine folks. Will be hosting this seminar in a half hour - all are free to join.
Helen Zhou:
"Towards Characterizing and Adapting to Shifts in Medical Data over Time" weillcornell.zoom.us/j/9258127170... 437063
Helen Zhou:
"Towards Characterizing and Adapting to Shifts in Medical Data over Time" weillcornell.zoom.us/j/9258127170... 437063